Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T18:53:45.363Z.
Calculation as of: 2026-10-06T18:53:45.363Z.
Quote observation: 2026-10-06T18:49:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a8ce9bd0ffb1cb5d8a686ad50c5c0fc76176a0385911c5cc34bdb5d73fbb2f35
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Yarrow Bioscience Inc
Market Cap
$178.83M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$180.89M
Free Cash Flow Yield
N/A
TTM Avg
4.80%
3Y Avg
4.80%
5Y Avg
4.80%
Market Cap
$180.99M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$183.17M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$173.76M
Free Cash Flow Yield
N/A
TTM Avg
6.14%
3Y Avg
6.14%
5Y Avg
6.14%
Market Cap
$173.94M
Free Cash Flow Yield
N/A
TTM Avg
7.28%
3Y Avg
8.72%
5Y Avg
8.72%
Market Cap
$184.04M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$171.13M
Free Cash Flow Yield
N/A
TTM Avg
0.25%
3Y Avg
0.25%
5Y Avg
0.25%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Yarrow Bioscience Inc (YARW) | $178.83M | N/A | N/A | N/A | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $180.89M | N/A | 4.80% | 4.80% | 4.80% |
| Compass Therapeutics, Inc. (CMPX)vs › | $180.99M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $183.17M | N/A | N/A | N/A | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | N/A | 6.14% | 6.14% | 6.14% |
| Journey Medical Corporation (DERM)vs › | $173.94M | N/A | 7.28% | 8.72% | 8.72% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $184.04M | N/A | N/A | N/A | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $171.13M | N/A | 0.25% | 0.25% | 0.25% |
| Cue Biopharma, Inc. (CUE)vs › | $169.91M | N/A | N/A | N/A | N/A |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.85M | 12.27% | 7.35% | 3.01% | 3.15% |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
105.68%
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
